Acute CardiovascalureCare Congress 2019 State of the Art lecture: present and future of antithrombotic strategies after TAVR ESC congress 2018 Maintenance of anti-thrombotic therapy after TAVI ...
Ticagrelor vs prasugrel in acute phase of primary percutaneous coronary intervention under treatment with abciximab: safety and efficacy
Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction
Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs
Antiplatelet therapy use in atrial fibrillation patients taking oral anticoagulation: an analysis of adverse outcomes from the FANTASIIA registry.
Estimated effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to optimally anticoagulated real-world atrial fibrillation patients taking acenocoumarol
Is there an obesity paradox for adverse outcomes in patients with atrial fibrillation? insights from the FANTASIIA registry
Long term cardiovascular risk prediction in Real-World atrial fibrillation patients:
Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Atrial Fibrillation patients.The FANTASIIA Registry.
In this regard, a recent trial of postconditioning in 1,234 patients undergoing PCI failed to reduce the composite outcome of death from any cause and hospitalization for heart failure. (4) In 2015, ...